INTRODUCTION: Many patients who have had Parkinson's disease (PD) for several years will present severe motor fluctuations and dyskinesias which require more aggressive therapies. The different approaches which are now available include deep brain stimulation of the subthalamic nucleus or medial globus pallidus, subcutaneous infusion of apomorphine, and intestinal infusion of levodopa-carbidopa. OBJECTIVE: To define the indications and results for the 3 available therapies for advanced PD. DEVELOPMENT: Exhaustive review of the literature concerning the indications and results of deep brain stimulation, subcutaneous apomorphine infusion and duodenal infusion of levodopa/carbidopa gel to treat patients with advanced Parkinson disease. CONCLUSIONS: Although numerous studies have confirmed the efficacy of the 3 different therapies in advanced PD, there are no comparative studies that would allow us to define the best candidate for each technique.
INTRODUCTION: Many patients who have had Parkinson's disease (PD) for several years will present severe motor fluctuations and dyskinesias which require more aggressive therapies. The different approaches which are now available include deep brain stimulation of the subthalamic nucleus or medial globus pallidus, subcutaneous infusion of apomorphine, and intestinal infusion of levodopa-carbidopa. OBJECTIVE: To define the indications and results for the 3 available therapies for advanced PD. DEVELOPMENT: Exhaustive review of the literature concerning the indications and results of deep brain stimulation, subcutaneous apomorphine infusion and duodenal infusion of levodopa/carbidopa gel to treat patients with advanced Parkinson disease. CONCLUSIONS: Although numerous studies have confirmed the efficacy of the 3 different therapies in advanced PD, there are no comparative studies that would allow us to define the best candidate for each technique.
Authors: Maria José Catalán; Angelo Antonini; Matilde Calopa; Ovidiu Băjenaru; Oriol de Fábregues; Adolfo Mínguez-Castellanos; Per Odin; José Manuel García-Moreno; Stephen W Pedersen; Zvezdan Pirtošek; Jaime Kulisevsky Journal: eNeurologicalSci Date: 2017-07-02
Authors: Edwin Daniel Oña; Carlos Balaguer; Roberto Cano-de la Cuerda; Susana Collado-Vázquez; Alberto Jardón Journal: Comput Intell Neurosci Date: 2018-04-11
Authors: Matthew Rosebraugh; Hari V Kalluri; Wei Liu; Charles Locke; Dilraj Sidhu; Jian-Hwa Han; Janet Benesh Journal: Pharmacol Res Perspect Date: 2019-04
Authors: Irene A Malaty; Pablo Martinez-Martin; K Ray Chaudhuri; Per Odin; Matej Skorvanek; Joohi Jimenez-Shahed; Michael J Soileau; Susanna Lindvall; Josefa Domingos; Sarah Jones; Ali Alobaidi; Yash J Jalundhwala; Prasanna L Kandukuri; Koray Onuk; Lars Bergmann; Samira Femia; Michelle Y Lee; Jack Wright; Angelo Antonini Journal: BMC Neurol Date: 2022-01-24 Impact factor: 2.474
Authors: Angelo Antonini; Rajesh Pahwa; Per Odin; Tove Henriksen; Michael J Soileau; Ramon Rodriguez-Cruz; Stuart H Isaacson; Aristide Merola; Susanna Lindvall; Josefa Domingos; Ali Alobaidi; Yash J Jalundhwala; Prasanna L Kandukuri; Juan Carlos Parra; Pavnit K Kukreja; Koray Onuk; Lars Bergmann; James Pike; K Ray Chaudhuri Journal: Neurol Ther Date: 2022-01-11